Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Telehealth company Him & Hers Health is taking a very different approach to its Super Bowl ad this year - as its new ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...

We are recommending Skye Bioscience Inc. (SKYE) as our next investment opportunity in treating metabolic disease/obesity. Skye is developing a peripheral restricted CB1 antibody — nimacimab — to treat ...

Klarity - Weight Loss Looking for weight loss options? GLP-1 agonist medications, originally designed to manage type 2 ...

Ozempic and other semaglutide medications have skyrocketed in popularity as weight-loss aids, with prescriptions surging by ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

Breakthrough in diabetes treatment! The US FDA approves Ozempic for reducing kidney disease risk in diabetic patients. Learn ...